This dataset corresponds to the quantification results carried out for skin cancer platforms developed by tissue engineering and control platforms analyzed in the manuscript entitled "Engineering a Squamous Cell Carcinoma Platform Based on an Approved ATMP to Enable Precision Therapeutics and Oncology Drug Discovery". Bioengineered models can be used to better understand complex biological processes such as cancer development but also as a drug testing platform in order to reduce the use of animals in research as well as they do not fully recreate human conditions. For this reason, our study aimed to generate a biomimetic three-dimensional squamous cell carcinoma (SCC) model by bioengineering the clinical approved used skin substitute (UGRSKIN). By evaluating its biological fidelity, we established a robust tool for personalized medicine research and oncology research. Firstly, the morphological and phenotypical analysis performed by histological and histochemical staining techniques showed that our model recreates disease-like histopathological features related to tumor development processes. Additionally, gene assessment confirmed the results previously observed as well as demonstrated the use of our model (UGRSKIN-CM) as a platform for understanding genetic alterations responsible for tumorigenesis. Finally, the model was also subjected to pharmacological validation by using a tyrosine kinase inhibitor (Gefitinib). The results confirm that our model does not only recreate the histoarchitecture but also the biological response against an anti-tumor drug. Considering the results obtained and the potential to create unique, patient-specific and customizable platforms by incorporating autologous cells make UGRSKIN-CM an ideal tool in the field of personalized medicine. The original data obtained for the quantitative analyses of each component are shown in this dataset.